Neion Bio Raises $11 Million in Seed Funding
Neion Bio, a biotechnology company based in New York City, has successfully raised $11 million in a seed funding round. The round was led by Caffeinated Capital, with additional investments from Basis Set Ventures and Haystack VC. Neion Bio, founded by Dimi Kellari and Sam Levin, is focused on transforming natural molecular factories into a cutting-edge biomanufacturing platform.
Innovative Biomanufacturing Approach
Neion Bio is developing a platform that leverages genetic engineering to produce biologics using eggs. This novel approach aims to reduce costs and improve the scalability of biologic medicines compared to traditional methods. The company's Raptor™ platform is designed to facilitate localized and resilient production of therapeutic proteins, streamlining operations and minimizing the need for expensive infrastructure.
Strategic Use of Funds
The recent funding will enable Neion Bio to further develop its biomanufacturing platform and expand its commercial partnerships. The company has already signed a co-development and supply agreement with a major global pharmaceutical firm. This deal includes the co-development of up to three monoclonal antibodies, with provisions for upfront payments, milestone-based compensation, and profit sharing upon commercialization.
Leadership and Vision
Neion Bio's leadership includes Co-Founder and CEO Dimi Kellari, Co-Founder and CTO Sam Levin, and Chief Scientific Officer Dr. Sven Bocklandt. The company has also appointed Ming Li as President of Commercial Operations to enhance its strategic partnerships and commercial strategies.
CEO Dimi Kellari emphasized the transformative potential of their platform, stating: "Biopharma manufacturing has not changed in decades, and has become a major bottleneck in advancing medical breakthroughs. Neion Bio’s platform removes the capital intensity and process constraints of traditional biomanufacturing, enabling highly scalable and resilient production."
Future Directions
With this infusion of capital, Neion Bio is poised to continue its mission of revolutionizing biomanufacturing. By utilizing eggs as a biological production system, the company aims to offer a scalable and cost-effective alternative to existing cell culture-based methods. Such advancements could significantly impact the accessibility and localization of critical medicines.